Excessive daytime sleepiness

MyCare Medical Continues Major Service Area Expansion - Partners with Jacinto Medical Group to Bring Expanded Health Care to Houston Area

Retrieved on: 
Friday, December 23, 2022
Organization, Dementia, Quality of life, Excessive daytime sleepiness, Topical steroid withdrawal, Muscle, Patient, Headache, SunMed BRT station, Social media, Compartment syndrome, Brain, Health, Partnership, Growth, Epilepsy, Stroke, GTA MyCar, Spinal cord, Pain management, Sleep, Snoring, Diabetes, Multiple sclerosis, Medicare, Insomnia, Midsayap Diagnostic Center and Hospital, Family medicine, Narcolepsy, Sleep apnea, Alzheimer's disease, Insulin resistance, Radiology, Parkinson's disease, Jacinto, Physician, Arthritis, Acquisition, JMG, Neurology, Pharmaceutical industry, Health insurance, Medical imaging, Psychiatry

TAMPA, Fla., Dec. 23, 2022 /PRNewswire/ -- MyCare Medical announced it had recently acquired Jacinto Medical Group (JMG) located in Baytown and LaPorte, Texas.

Key Points: 
  • TAMPA, Fla., Dec. 23, 2022 /PRNewswire/ -- MyCare Medical announced it had recently acquired Jacinto Medical Group (JMG) located in Baytown and LaPorte, Texas.
  • "This union will marry strength with strength and will form a best-in-class managed platform," said Gautam Shirhattikar, MyCare CEO.
  • "Together with JMG, MyCare Medical now reaches a greater population of Medicare patients in Southeast Texas.
  • Founded by and led by physicians, MyCare Medical (formerly SunMed & Hernando Pascal Primary Care) is a Primary Care Group that has served the greater Tampa Bay area for more than 15 years.

Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book

Retrieved on: 
Friday, November 18, 2022
Securities and Exchange Commission (Philippines), Jazz Pharmaceuticals, Avadel Pharmaceuticals, Cataplexy, Food, Narcolepsy, Safety, Knowledge, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Delaware Court of Common Pleas, Somnolence, Drug Quality and Security Act, Excessive daytime sleepiness, Delaware Court, 1836 U.S. Patent Office fire, Security (finance), Sodium oxybate, District court, REMS, NDA, EDS, Orange Book, Patent, Hearing, Motion, FDA, Pharmaceutical industry

DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the United States District Court for the District of Delaware (the “Delaware Court”) ordered Jazz Pharmaceuticals to delist U.S. Patent No. 8731963 (the “REMS Patent”) from the U.S. Food and Drug Administration’s (“FDA”) Orange Book. With this decision, Avadel seeks to accelerate the FDA’s final approval decision for LUMRYZ™, a once-at-bedtime investigational formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Key Points: 
  • We are pleased with the courts decision in favor of delisting the REMS Patent from the FDAs Orange Book, potentially accelerating a final approval.
  • On July 18, 2022, LUMRYZ received tentative approval from the FDA, with potential final approval pending disposition of the REMS Patent.
  • On October 25, 2022, a Markman hearing was held in which Avadel renewed its request for expedited consideration of its pending motion to have the REMS Patent delisted from FDAs Orange Book.
  • With the issuance of this ruling, Avadel intends to seek final FDA approval for LUMRYZ upon removal of the REMS Patent from the FDAs Orange Book.

The Worldwide Narcolepsy Therapeutics Industry is Expected to Reach $5 Billion by 2028 at a 10.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
General Health, Pharmaceutical, Health, Investment, Sodium oxybate, Gamma-Hydroxybutyric acid, Narcolepsy, Hypersomnia, Economic development, Excessive daytime sleepiness, Insomnia, Modafinil, Life, Pharmacokinetics, Dopamine, Person, Emotion, Stimulant, NIH, Hypnagogia, EDS, National Institute for Health and Care Excellence, Cataplexy, Union, Restless legs syndrome, Sleep apnea, Norepinephrine, Sleep paralysis, GABAB, Diagnosis, Health, Patient, Pharmaceutical industry

The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.

Key Points: 
  • The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
  • Modafinil, armodafinil, and stimulants are only a few of the medications used to treat narcolepsy.
  • Others include sodium oxybate and venlafaxine, which are used to treat the symptoms of sleep paralysis and sleep-related hallucinations (e.g.
  • One of the main factors holding back the narcolepsy market is the high cost of narcolepsy diagnosis and treatment.

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Retrieved on: 
Thursday, October 27, 2022
Boxed warning, Nasdaq MarketSite, Narcolepsy, Company, CNS, OSA, Dopamine, MD, NASDAQ, Depression, Wakefulness, Breakthrough therapy, Food, Physician, EDS, Excessive daytime sleepiness, Food and Drug Administration, NMDA, Schedule, Dextromethorphan, Hydrogen chloride, MDD, Patient, Bupropion, Adult, Research, GLOBE, Nasdaq, Obstructive sleep apnea, Therapy, FDA, HBR, Times Square, CYP2D6, Medication, Migraine, Central nervous system, Pharmaceutical industry, Solriamfetol, COVID-19

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsomes Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY in the United States by prescription.

Key Points: 
  • NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsomes Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY in the United States by prescription.
  • We are honored to ring NASDAQs opening bell to commemorate the availability of Auvelity by prescription and the hard work and dedication of the Axsome team which made it possible.
  • The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, NY.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.

Global Narcolepsy Drugs Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

Retrieved on: 
Monday, October 24, 2022
Adoption, Globe, Sleep paralysis, Therapy, Prevalence, Wakefulness, Narcolepsy, Hallucination, Novartis, CAGR, Somnolence, Patient, Sleep, Research, Disorder, EDS, R, Excessive daytime sleepiness, Takeda Pharmaceutical Company, Industry, Neurology, Awareness, Sodium oxybate, Adult, Insomnia, Cataplexy, COVID-19, Central nervous system, Jazz Pharmaceuticals, Pharmaceutical industry, Potash, Growth

DUBLIN, Oct. 24, 2022 /PRNewswire/ -- The "Narcolepsy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 24, 2022 /PRNewswire/ -- The "Narcolepsy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market reached a value of US$ 2.84 Billion in 2021.
  • What has been the impact of COVID-19 on the global narcolepsy drugs market?
  • What is the structure of the global narcolepsy drugs market and who are the key players?

The Worldwide Insomnia Industry is Projected to Reach $6.3 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Health, Other Health, People, Thought, Sleep disorder, Growth, Population, CAGR, Porter's five forces analysis, Sleep, Depression, Disorder, WHO, Excessive daytime sleepiness, Irritability, Menopause, World Health Organization, Circadian rhythm, Chronic pain, Hyperthyroidism, Pharmaceutical industry, Retail, Insomnia

The "Insomnia Market By Therapy Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insomnia Market By Therapy Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global insomnia market was valued at $ 4,318.9 million in 2020, and is projected to reach $ 6,315.9 million by 2030, registering a CAGR of 3.9% from 2021 to 2030.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the insomnia market analysis from 2020 to 2030 to identify the prevailing insomnia market opportunity.
  • The report includes the analysis of the regional as well as global insomnia market trends, key players, market segments, application areas, and market growth strategies.

Insights on the Narcolepsy Drugs Global Market to 2027 - by Type, Disease Type, Therapeutic Type and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Health, Pharmaceutical, Adoption, Globe, Sleep paralysis, Prevalence, Growth, Wakefulness, Narcolepsy, Hallucination, Somnolence, Patient, Sleep, Research, Disorder, EDS, R, Excessive daytime sleepiness, Industry, Neurology, Awareness, Adult, Sodium oxybate, Insomnia, Cataplexy, COVID-19, Central nervous system, Pharmaceutical industry, Potash

Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants.

Key Points: 
  • Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants.
  • Key Questions Answered in This Report:
    How has the global narcolepsy drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global narcolepsy drugs market?
  • What is the structure of the global narcolepsy drugs market and who are the key players?

HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

Retrieved on: 
Thursday, September 22, 2022
Paragon, Heart, American Academy, Harmony Project, Task force, Narcolepsy, Empowerment, The Task Force for Global Health, Social media, Patient, Excessive daytime sleepiness, NASDAQ, Communication, Conditional sentence, Workforce, Columbia University, Division, Organization, Life, Idiopathic hypersomnia, Person, REST, Prader–Willi syndrome, Insurance, Neurology, EDS, Epidemiology, Kleine–Levin syndrome, Goal, Harmony, Cardiovascular disease, Empathy, Therapy, Lists of diseases, Sleep disorder, LLC, Plymouth Meeting, Pennsylvania, Program, Progress, UNITE, Caregiver, Enterprise for High School Students, Awareness, American Academy of Neurology, Education, Pharmaceutical industry, Medical device, Medicine, Cardiology, Sleep

PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated todeveloping and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.

Key Points: 
  • PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated todeveloping and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
  • This award funds innovative programs that address health disparities and inequities in rare neurological disease and sleep disorder communities.
  • Combined with the Patients at the Heart awards, total funding for these two programs has now increased to $380,000 in over the last four years.
  • "In recognition of World Narcolepsy Day, we are pleased to announce this year's recipients of the Patients at the Heart and Progress at the Heart award programs.

New 12-month Results from the VATRAC Trial Confirm Durable Efficacy of Aerin Medical’s VivAer® in Patients with Nasal Valve Collapse

Retrieved on: 
Tuesday, September 6, 2022
Science, Other Science, Research, Medical Supplies, Health, Medical Devices, Clinical Trials, Other Health, Otorhinolaryngology, ENT, Fatigue, JAMA Otolaryngology–Head & Neck Surgery, Technology, Division, Safety, CEO, NAO, YouTube, Nose, Exercise, Solution, Randomized controlled trial, International Forum of Allergy & Rhinology, Physician, LinkedIn, NVC, Ear, Network congestion, Headache, Quality of life, Multimedia, Sleep, Somnolence, Patient, Instagram, FDA, Eastern Virginia Medical School, Nasal congestion, Twitter, Excessive daytime sleepiness, Snoring, Prevalence, Epworth Sleepiness Scale, Freezing, CE marking, Adoption, Pharmaceutical industry, Birth control, Allergy, Facebook

This study demonstrates that treatment with VivAer is a compelling non-invasive alternative for NAO patients and reinforces physician confidence in the consistent and lasting results of this treatment.

Key Points: 
  • This study demonstrates that treatment with VivAer is a compelling non-invasive alternative for NAO patients and reinforces physician confidence in the consistent and lasting results of this treatment.
  • After primary endpoint analysis and unblinding, 31 patients were eligible for crossover, and all elected to undergo active VivAer treatment.
  • The VATRAC study outcomes demonstrate ongoing effectiveness and safety of VivAer, with treated patients reporting durable improvement from baseline at 12 months post-procedure.
  • 1 Silvers et al., Temperature-controlled radiofrequency device treatment of the nasal valve for nasal airway obstruction: A randomized controlled trial.

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Cataplexy, NDA, Forward-looking statement, GLOBE, Securities Exchange Act of 1934, SEC, Lesbian flag, Sodium oxybate, District, Patent, Security (finance), Orange Book, Knowledge, Workforce, REMS, Income, Douglas v. U.S. District Court ex rel Talk America, Court, Narcolepsy, Patient, Review, EDS, Company, Avadel Pharmaceuticals, International, Excessive daytime sleepiness, Safety, District court, 1836 U.S. Patent Office fire, Securities Act of 1933, Webcast, Food and Drug Administration, Nasdaq, Certification, Food, Fine chemical, Pharmaceutical industry, Online gambling, Risk management, Generic drug

ET

Key Points: 
  • ET
    DUBLIN, Ireland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2022.
  • R&D expenses were $4.5 million in the quarter ended June 30, 2022, compared to $6.8 million for the same period in 2021.
  • SG&A expenses were $21.8 million in the quarter ended June 30, 2022, compared to $15.2 million for the same period in 2021.
  • These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events.